Lilly to acquire gene editing specialists Verve Therapeutics
Eli Lilly and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead programme… Read More
